Compare HAWK & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAWK | XNCR |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2026 | 2013 |
| Metric | HAWK | XNCR |
|---|---|---|
| Price | $14.63 | $24.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $32.56 | $31.42 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $84.87 | $14.05 |
| Revenue Next Year | $24.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $15.21 | $10.38 |
| 52 Week High | $25.71 | $30.61 |
| Indicator | HAWK | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 28.61 | 51.52 |
| Support Level | N/A | $23.36 |
| Resistance Level | $17.42 | $30.61 |
| Average True Range (ATR) | 0.68 | 1.03 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 2.26 | 55.23 |
Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.